Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Despite the Turnaround, GE Stock Faces Near-term Pressure

By Thomas Niel, InvestorPlace Contributor

Though the turnaround in GE stock generated interest previously, the coronavirus imposes fundamental headwinds, potentially hurting General Electric's industrial units.

3 Tech Stocks to Sell As the Market Trends Lower

By Thomas Niel, InvestorPlace Contributor

With the markets currently trending lower, these three names are key tech stocks to sell before prices retreat back to prior levels.

Facing Headwinds, Luckin Stock Could Drop Lower

By Thomas Niel, InvestorPlace Contributor

Even if a recent "short report" is inaccurate, LK stock may head lower as continued growth proves to be unsustainable.

Don’t Buy the Dip: Alibaba Stock Could Go Lower

By Thomas Niel, InvestorPlace Contributor

Valuation may look reasonable compared to Amazon. But considering past P/E ratios, shares could easily fall back below $170/share. Add in the risk of impacted growth. Top it off with US-China trade tensions flaring up again. Alibaba stock could easily wind up back to where it was in the middle of 2019.

Look Anywhere but Acasti Pharma Stock for Opportunity

By Thomas Niel, InvestorPlace Contributor

It doesn't look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital. A dilutive equity raise would push shares down further. Even if they do a reverse stock split. Yet, shares aren't guaranteed to hit zero. If their subsequent actions with CaPre pay off, shares could soar as the prospective drug gets back on track.

There Is No Good Play When It Comes to INO Stock

By Thomas Niel, InvestorPlace Contributor

With this in mind, what's the best play? Stay on the sidelines. INO stock is too overvalued to go long. But, unpredictability makes it a weak short candidate. Staying on the fence may be the best move.

Teva Stock Was a Good Buy Last Fall, but It Topped out After This Rally

By Thomas Niel, InvestorPlace Contributor

TEVA stock was a great contrarian play last fall. With opioid liabilities hanging like an anvil over the company, shares were priced for disaster. More than doubling from their 2019 lows, I wouldn't say Teva shares are now "priced to perfection". But, the current share price may be pricing in much of the upside. Bottom Line? Consider TEVA stock a hold. With markets facing volatility, a better entry point could spring up down the road.

3 Baby Boomer Stocks to Buy and Hold for the Long Haul

By Thomas Niel, InvestorPlace Contributor

Baby boomers aren't going anywhere anytime soon. So as they continue to spend in their golden years, consider these baby boomer stocks.

Wait for Market Uncertainty to Cool Before Buying Intel Stock

By Thomas Niel, InvestorPlace Contributor

Intel stock could be cheap today. But "buying the dip" this week might as well be called "catching a falling knife". Based on historical P/E data, INTC could easily fall below $50/share. At that price point, shares could be a buy. But until then, take your time, and stay on the sidelines.

As Uncertainty Remains, Tread Carefully With iQIYI Stock Before Its Q4 Earnings

By Thomas Niel, InvestorPlace Contributor

The coronavirus has barely impacted IQ stock. Yet, as uncertainty remains, it may pay to wait until after earnings to enter a position.

Load More